Diabetes and insulin management software company Glytec and pharmaceutical firm Roche, are teaming up to allow the use of Glytec’s software in connection with Roche’s point-of-care smart-device hospital blood glucose system cobas pulse, in the U.S. and global markets.
According to Roche, cobas pulse’s strip architecture provides lab-like results and minimizes the need to repeat tests. The system can be used on all patient populations, including neonates and intensive care patients.
Glytec’s FDA-cleared insulin dosing decision support software Glucommander, is used for inpatient diabetes treatment and to help healthcare providers maximize glycemic management strategies and enhance outcomes.
The collaboration coincides with Glytec’s strategy to empower synergistic diabetes and insulin management. By capitalizing on Roche’s global presence and Glytec’s stable track record, the joint venture aims to elevate patient safety, strengthen the cost-effectiveness of care, and improve outcomes.
“Diabetes knows no borders, profoundly impacting hospital diabetes management and patient outcomes worldwide,” Robby Booth, cofounder and chief strategy officer at Glytec, said in a statement. “We are proud of our expanded collaboration with Roche, which reaffirms our commitment to addressing this critical healthcare challenge for patients, providers and payers and positively impacting lives worldwide.”
THE LARGER TREND
In August, Glytec announced support for CMS’s new mandatory reporting requirements aimed at improving hyper- and hypoglycemia measures. The move advances diabetes excellence across the U.S., particularly benefiting rural and underserved communities, and enhances broader value-based care initiatives.
In June, the company announced a strategic partnership with Major Health Partners (MHP), a community-based hospital in Shelbyville, Indiana, that integrated Glytec’s FDA-cleared Glucommander software. MHP aims to use the software to standardize insulin titration and reduce risks of severe hypoglycemia.
In May, Glytec announced a partnership with the Cleveland Clinic to deliver its insulin management software platform to UH Cleveland Medical Center. The software platform leverages evidence-based algorithms and real-time data analysis to personalize dosing for all insulin-requiring patients.
In 2021, the insulin management software company received $21 million in funding from Silicon Valley Bank, Savitr Capital and other private investors. It collected $9 million in debt financing from SVB and $12 million in equity investments led by Savitr positions.
